威尔药业实控人方拟减持 其46.9%持股已被质押

Core Viewpoint - Weier Pharmaceutical (603351.SH) announced a plan for shareholders to reduce their stakes through centralized bidding, with a focus on the employee stock ownership platform, Shuntai Zonghua [1] Group 1: Shareholder Reduction Plan - Shuntai Zonghua intends to reduce its holdings by up to 1,354,390 shares, representing no more than 1% of the total share capital, between August 20, 2025, and November 17, 2025 [1] - The company's vice president, Zou Jianguo, plans to indirectly reduce his holdings by up to 90,089 shares, while supervisor Li Youhong will reduce his holdings by up to 25,633 shares, both not exceeding 25% of their indirect holdings [1] - The reduction plan does not include shares held by the company's controlling shareholders and actual controllers, Wu Renrong, Gao Zhengsong, and Chen Xinguo, who will not reduce their stakes in any manner [1] Group 2: Pledged Shares - As of the latest disclosure, Wu Renrong, Gao Zhengsong, Chen Xinguo, and Shuntai Zonghua have pledged a total of 26,680,000 shares, accounting for 46.90% of their holdings and 19.70% of the company's total share capital [2] - Wu Renrong holds 18,521,981 shares (13.68%), with 8,570,000 shares pledged, while Gao Zhengsong and Chen Xinguo hold 14,111,986 shares (10.42%) each, with 8,460,000 and 5,350,000 shares pledged respectively [3] Group 3: Company Financials - Weier Pharmaceutical raised a total of 591,667,850.00 yuan from its initial public offering, with a net amount of 538,497,386.71 yuan intended for projects including a 20,000t/a injection drug excipient and general pharmaceutical excipient production base [4] - The total issuance costs amounted to 53,170,463.29 yuan, with underwriting and sponsorship fees of 41,509,433.96 yuan [5]